bio-equity (@BioEquity) header
bio-equity (@BioEquity) profile picture

bio-equity

@BioEquity

AKA 2Blockchains

Joined May 2014
  • Tweets341
  • Following133
  • Followers77
6Media
Photo by bio-equity (@BioEquity)Photo by bio-equity (@BioEquity)Photo by bio-equity (@BioEquity)Photo by bio-equity (@BioEquity)Photo by bio-equity (@BioEquity)Photo by bio-equity (@BioEquity)
My #ASCO18 preview. endpts.com/brad-loncars-asco…
Brad Loncar's ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars...

Brad Loncar's ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars...

To prepare for the future, it helps to look back on what has happened in the past. ASCO is a great benchmark for doing that. Drug development does not happen ...

endpoints.news
14
62
14
152
Mylan turns screws on Pfizer over EpiPen shortage; sends crack team to troubled St Louis factory to try to fix manufacturing issues. $Myl $pfe nitter.cf/financialtimes/status/…
Financial Times (@FinancialTimes) profile pictureFinancial Times
@FinancialTimes24 May 2018
Pfizer under pressure to resolve shortage of life-saving EpiPen on.ft.com/2IFn3iI
6
4
$ALXN why????? 855 MM deal to buy a big pot of pricing concerns target on its back..
5
2
4
bio-equity retweeted
Odi Bruckman (@odibro) profile picture
Odi Bruckman@odibro2 Apr 2018
$ALKS Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
9
3
9
$BHVN stats sign.. but clin irrelevant with this kind of efficacy delta.. bye bye..
4
7
How to improve your listening skills: 1 talk less 2 do not interrupt 3 maintain direct eye contact 4 put your phone down 5 listen with your eyes; look for the unsaid 6 be interested 7 if you are waiting for a pause, so that you can speak, then you're not actively listening
11
461
21
865
Scientists are real heroes. 5 billion lives saved by some 100 or so incredible minds. From Steven Pinker's Enlightenment Now.
Image from Jonathan Wai (@JonathanLWai)
98
2,488
193
4,749
$OMER simple math to work out that Omidria can be priced cheaply enough to take most of the market & still bring in ~100M in annual revenue in US. & with pricing worked out, they can finally expand into EU and Asia.
1
3
Replying to @espn
@ESPN please nominate Coach Aaron Feis, our fallen hometown HERO during the MSD school shooting for 2018 @ESPYS Arthur Ashe Courage Award – at Chuo-ku, Tokyo
32
2,505
87
5,272
bio-equity retweeted
Odi Bruckman (@odibro) profile picture
Odi Bruckman@odibro8 Feb 2018
$VBLT Receives undisclosed Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan finance.yahoo.com/news/vbl-t…
1
1
1
Here's Bristol's press release. This news on the TMB biomarker is potentially a very important finding for immunotherapy, if true. This will have been an important study result for that reason alone. investors.bms.com/iframes/pr…

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the...

First and only Phase 3 trial to evaluate and show a highly statistically significant PFS benefit with an I-O/I-O combination in first-line NSCLC patients with high TMB, regardless of PD-L1 expression...

investors.bms.com
4
14
21
bio-equity retweeted
CNBC (@CNBC) profile picture
CNBC
@CNBC30 Jan 2018
BREAKING: Berkshire Hathaway, Amazon, and JPMorgan Chase partner on health care for their US employees through creation of “an independent company that is free from profit-making incentives and constraints” cnbc.com/2018/01/30/amazon-b…
Amazon, Berkshire Hathaway, and JPMorgan Chase to partner on US employee health care

Amazon, Berkshire Hathaway, and JPMorgan Chase to partner on US employee health care

Amazon, Berkshire Hathaway and JPMorgan announce plans to partner on ways to cut health care costs and improve services for U.S. employees.

cnbc.com
123
997
363
1,623
This is really cool: $MRK spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D - endpts.com/merck-spinout-gra… by @JohnCEndpts
Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D

Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D

Terry Roemer did a lot more than clean out his desk when he decided to leave Merck after a 13-year career developing antibodies at the pharma giant. With R&D chief ...

endpoints.news
5
2
17
Upgrades 1/26: $AGI $AROC $AUY $CEQP $COMM $EGN $EGO $EXPO $FE $GILD $GSS $INTC $JACK $KBH $MAC $MRTN $NGG $SITE $SLG $STM $TRV $WHR $ZG
2
Downgrades 1/26: $AG $AZPN $BANC $BBBY $CNS $FHB $FSB $FTNT $GDS $GE $MBFI $NWL $QD $RCI $SBUX $SCMP $TAHO $THO $UNP $WGO $WHR
2
$AERI prices offering. secfilings.nasdaq.com/filing…
1
1
Infectious diseases (e.g., flu, Ebola, Zika, SARS) know no boundaries! This is penny wise and pound foolish! #publichealth wsj.com/articles/cdc-to-scal…
2
9
1
12
bio-equity retweeted
Vk (@biotechinvstr) profile picture
Vk
@biotechinvstr16 Jan 2018
$EIGR complete fail, to discontinue development in PAH. No signal whatsoever
2
5
6
bio-equity retweeted
M (@bio_clouseau) profile picture
M@bio_clouseau10 Jan 2018
$RXDX had another bidder at 25 per share before $RHHBY hurried up and made an offer. EMA PRIME for TRK seems to have been a factor in interest by other bidder and Roche $LOXO sec.gov/Archives/edgar/data/…
1
13
13
Aiman Shalabi from @CancerResearch says there are now: 26 Immunotherapies approved globally. 271 targets being studied. 162 CAR-T agents in the clinic.
Image from Brad Loncar (@bradloncar)
Image from Brad Loncar (@bradloncar)
Image from Brad Loncar (@bradloncar)
Image from Brad Loncar (@bradloncar)
44
4
56
Load more